

1 **SUPPLEMENTARY MATERIALS**

2

3 **SUPPLEMENTARY METHODS**

4

5 **Definition of recently acquired HCV infection**

6

7 Recently acquired HCV infection was identified if any one of the following occurred: (i) detectable  
8 HCV RNA within 6 months after a negative HCV RNA or HCV serology test, (ii) detectable HCV RNA  
9 and acute clinical hepatitis within 5 months prior to screening visit (ALT  $\geq$ 250 IU/L with normal ALT  
10 within the preceding 8 months or ALT  $\geq$ 500 IU/L with either no measured ALT or with abnormal ALT  
11 within the preceding 8 months), (iii) reinfection defined by documented *de novo* infection after prior  
12 post-treatment clearance (defined by one negative HCV RNA  $\geq$ 6 months after end of treatment) or  
13 spontaneously (defined by two negative HCV RNA a minimum of 6 months apart or documented  
14 infection with a new viral strain, confirmed by phylogenetic or genotypic analysis) within 5 months  
15 prior screening, or (iv) patients having reported a risk factor for HCV transmission (traumatic sexual  
16 intercourse, intranasal, rectal or intravenous drug use)  $\geq$ 6 months and presenting a negative HCV  
17 RNA or HCV serology test within 12 months.

18 **SUPPLEMENTARY TABLES**

19

20 **Table S1. Determining recently acquired HCV cases prior to treatment**

21

Definition	<i>n</i> (%)
Detectable HCV RNA detectable ≤6 months after negative HCV RNA	7 (23)
Detectable HCV RNA detectable ≤6 months after negative HCV serological test	9 (30)
Detectable HCV RNA and ALT ≥ 250 IU/L occurring ≤5 months prior to screening with normal ALT in the preceding 8 months	3 (10)
Detectable HCV RNA and ALT ≥ 500 IU/L occurring ≤5 months prior to screening with no measured ALT in the preceding 8 months	2 (7)
Detectable HCV RNA and ALT ≥ 500 IU/L occurring ≤5 months prior to screening with abnormal ALT in the preceding 8 months	2 (7)
Reported risk factor for HCV transmission 6 months prior to screening and negative HCV serology test 12 months prior to screening	4 (13)
Reported risk factor for HCV transmission 6 months prior to screening and negative HCV RNA 12 months prior to screening	3 (10)

22

23 **Table S2. Alcohol, tobacco, and Illicit drug use prior to treatment**

24

Current Alcohol use (N=29)*	
Never	4 (14)
Once or less per month	3 (10)
2-4 times per month	10 (34)
2-3 times per week	6 (21)
4 or more times per week	6 (21)
Number of glasses on a typical day* <sup>‡</sup>	
1-2	11 (44)
3-4	9 (36)
5-6	5 (20)
Current tobacco use (N=29)*	
Non-smoker	12 (41)
Former smoker	4 (14)
Current smoker	13 (45)
Packs smoked in the past 12 months <sup>¶</sup>	8.8 (4.3-19.4)
Illicit drug use in the past 12 months (N=24)	
Cannabis use	8 (44)
Number of times per month <sup>§</sup>	1.0 (0.2-2.0)
Cocaine use	11 (61)
Number of times per month <sup>§</sup>	1.5 (1.0-4.0)
Amphetamines	6 (33)
Number of times per month <sup>§</sup>	2.0 (1.0-3.0)
MDMA	8 (44)
Number of times per month <sup>§</sup>	1.0 (1.0-3.0)
Ketamine	1 (6)
Number of times per month <sup>§</sup>	1
3-methylmethcathinone	7 (39)
4-methylethcathinone	2 (11)
Methylenedioxypropyrene	1 (6)
γ-hydroxybutyrate	1 (6)
Nitrites	1 (6)
Methamphetamine	1 (6)

25 \*n (%) †Median (IQR)

26 ‡Among current alcohol users.

27 ¶Among current smokers.

28 §Among users of specific drugs.

29

30 **Table S3. Quality of life questionnaire items at beginning and end of follow-up**

31

	Study visit		<i>p</i> value
	W0 ( <i>n</i> =28)	PTW12 ( <i>n</i> =27)	
Physical functioning	0.75 (0-1.00)	1.00 (0.25-1.00)	0.4
Role physical	0.50 (0.50-0.88)	0.75 (0.50-1.00)	0.02
Bodily pain	1.00 (0.75-1.00)	1.00 (0.50-1.00)	0.9
General health	0.60 (0.60-0.85)	0.60 (0.60-0.85)	0.20
Vitality	0.50 (0.25-0.75)	0.50 (0.25-0.75)	0.9
Social functioning	0.50 (0.50-0.75)	0.50 (0.50-1.00)	0.5
Role emotional	0.50 (0.38-0.75)	0.75 (0.50-1.00)	0.02
Mental health	0.50 (0.38-0.69)	0.63 (0.50-0.75)	0.11

32 All statistics above are median (IQR). *P*-value determined from a fractional probit regression model  
 33 with cluster-adjusted variance estimators.

34

35